MedPath

MRS and 11C-methionine PET/CT in the Diagnosis of Glioma

Not Applicable
Completed
Conditions
Glioma
Interventions
Other: tumors are confirmed by surgery and pathology
Registration Number
NCT03009318
Lead Sponsor
Huashan Hospital
Brief Summary

MET PET and MRS are often performed as imaging tool for the differential diagnosis of gliomas. But both techniques have limitations causing misdiagnosis; thus, the investigators tried to combine these two imaging tools to study whether the combination of MET PET and MRS could raise the diagnosis ability of the radiological diagnosis of gliomas.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  1. Patients with non-enhancing supratentorial lesions shown by contrast-enhanced MRI
  2. No surgery, chemotherapy or radiotherapy history
  3. All patients gave written informed consent.
Exclusion Criteria
  1. Patients with infratentorial Neoplasms
  2. Patients with enhancing supratentorial lesions
  3. Recurrent gliomas after surgery
  4. Primary gliomas with history of radiotherapy or chemotherapy
  5. History of malignant tumours at any body site
  6. Inability to give informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
MRS imaging and 11C-MET PET/CTtumors are confirmed by surgery and pathologyEach patient underwent both MRS and MET PET before surgery.
Primary Outcome Measures
NameTimeMethod
Sensitivity of the combination of MRS and 11C-MET PET/CT5 years
Secondary Outcome Measures
NameTimeMethod
The relationship between 11C-MET PET/CT results and molecular pathogeneses5 years

Trial Locations

Locations (1)

Huashan hospital, Fudan university

🇨🇳

Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath